To the Editor: Packer et al. (Jan. 30 issue) 1 report the highly anticipated results of the SUMMIT trial, which compared tirzepatide with placebo in patients with heart failure with preserved ...

Tirzepatide targets two receptors in order to shrink fat cells and reduce the impacts that enlarged fat cells have on heart and kidney health. The drug is approved by the U.S. Food and Drug ...

NEW ORLEANS — For people with type 2 diabetes (T2D) inadequately controlled on submaximal dulaglutide (Trulicity) doses, switching to tirzepatide (Mounjaro) produces significantly greater A1c ...

Participants given tirzepatide lowered their HbA1c by a mean 0.77% more than those given a higher dulaglutide dose. More tirzepatide participants hit a weight loss threshold known for disease ...